37 C
Delhi
Saturday, July 12, 2025

Dr Reddy Labs launches Lenalidomide Capsules in US

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Dr. Reddy’s Labs on Thursday announced the launch of Lenalidomide Capsules in the US market, , a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA).

With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

‘We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

“Bringing a more affordable generic version to market creates greater patient access for this important drug.’

Dr. Reddy’s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.

Related articles

Confidence of New India Will Lead to Viksit Bharat: ‘Viksit Bharat: India @ 2047’ Author Aditya Pittie

Timely and meticulously researched, ‘Viksit Bharat: India @ 2047’, by author and thought leader, Aditya Pittie, provides a...

Voice of a Nation, Voice of the World: PM Modi’s Historic Addresses to Foreign Parliaments

An Unprecedented Journey of Words and WillIn the grand halls of parliaments across continents, where voices echo...

The Emerging Axis: Turkiye-Pakistan Bonhomie and Its Implications for India

The Ankara-Islamabad TangoIn the simmering July heat of Islamabad, the red carpet was rolled out for two...

SSI MantraM “Made in India” Surgical Robot Yatra Kicks Off India Tour, First Leg to Cover 1500 km Across Rajasthan

 ● In the first phase of the roadshow, SSI MantraM will cover key medical institutions across Jaipur, Jodhpur,...